The lawsuit, filed in 2013, claimed Teva persuaded physicians to write prescriptions for the drugs Copaxone, a multiple sclerosis treatment, and Azilect, a Parkinson’s drug, by paying them as speakers or consultants. Many of the speaker programs were allegedly sham events.
The lawsuit claimed Teva’s actions violated the False Claims Act and the Anti-Kickback Statute, which prohibit drugmakers from compensating physicians in any way to persuade them to prescribe their drugs.
A spokesperson for Teva told the Philadelphia Business Journal the drugmaker had no comment on the settlement.
Read the full article here.
More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
